Ascentage Pharma's BCL-2 inhibitor, lisaftoclax, is under China’s Priority Review for chronic lymphocytic leukemia and small ...

Some products have just become too expensive – and the prices aren't going down. Here are some buys that are no longer worth ...

Ariel Investments, an investment management company, released its “Ariel Global Fund” third-quarter 2024 investor letter. A ...

“Time Off for Clinical Trials," launched on Nov. 20, sees six of BioNJ’s biggest members—Amicus Therapeutics, Bristol Myers ...

Beyond Business School, a company founded by serial entrepreneurs Andra Ghibuțiu and Grégoire Vigroux, announces the final ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price ...

A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still ...

Australia’s medicines watchdog says parents should immediately stop giving a popular medicine to kids under the age of six, ...

In September 2024, UCB and Biogen reported successful results from their Phase III clinical trial of the PHOENYCS GO study, which tested dapirolizumab pegol as a treatment for moderate-to-severe ...

Sanofi has developed a simpler way to create site-specific antibody-to-mannose-6-phosphate (M6P) conjugates that eliminates the need for enzyme remodeling. This more straightforward method makes M6P ...

The growing comprehension of the pathogenesis of celiac disease has paved the way for the exploration of alternative treatment strategies. These novel approaches are aimed at addressing the ...